Rac1 activation in oral squamous cell carcinoma as a predictive factor associated with lymph node metastasis.
Cell migration
Epithelial–mesenchymal transition
Oral squamous cell carcinoma
Rac1
Secondary lymph node metastasis
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
19
04
2023
accepted:
19
06
2023
medline:
1
9
2023
pubmed:
7
7
2023
entrez:
7
7
2023
Statut:
ppublish
Résumé
Secondary lymph node metastasis (SLNM) indicates a poor prognosis, and limiting it can improve the survival rate in early-stage tongue squamous cell carcinoma (TSCC). Many factors have been identified as predictors of SLNM; however, there is no unified view. Ras-related C3 botulinum toxin substrate 1 (Rac1) was found to be a promoter of the epithelial-mesenchymal transition (EMT) and is also attracting attention as a new therapeutic target. This study aims to investigate the role of Rac1 in metastasis and its relationship with pathological findings in early-stage TSCC. Rac1 expression levels of 69 cases of stage I/II TSCC specimens and their association with clinicopathological characteristics were evaluated by immunohistochemical staining. The role of Rac1 in oral squamous cell carcinoma (OSCC) was examined after Rac1 in OSCC cell lines was silenced in vitro. High Rac1 expression was significantly associated with the depth of invasion (DOI), tumor budding (TB), vascular invasion, and SLNM (p < 0.05). Univariate analyses revealed that Rac1 expression, DOI, and TB were factors significantly associated with SLNM (p < 0.05). Moreover, our multivariate analysis suggested that Rac1 expression was the only independent determinant of SLNM. An in vitro study revealed that Rac1 downregulation tended to decrease cell migration and proliferation. Rac1 was suggested to be an important factor in the metastasis of OSCC, and it could be useful as a predictor of SLNM.
Identifiants
pubmed: 37418142
doi: 10.1007/s10147-023-02374-2
pii: 10.1007/s10147-023-02374-2
doi:
Substances chimiques
rac1 GTP-Binding Protein
EC 3.6.5.2
RAC1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1129-1138Informations de copyright
© 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Références
Dhanuthai K, Rojanawatsirivej S, Thosaporn W et al (2018) Oral cancer: a multicenter study. Med Oral Patol Oral Cir Bucal 23:e23–e29
pubmed: 29274153
Krishna Rao SV, MGK. KRoberts-Thomson et al (2013) Epidemiology of oral cancer in Asia in the past decade- an update(2000–2012). Asian Pac J cancer 14:5567–77
doi: 10.7314/APJCP.2013.14.10.5567
Tota JE, Anderson WF, Coffey C et al (2017) Rising incidence of oral tongue cancer among white men and women in the United States, 1973–2012. Oral Oncol 67:146–52
pubmed: 28351569
doi: 10.1016/j.oraloncology.2017.02.019
Report of Head and Neck Cancer Registry of Japan Clinical Statistics of Registered Patients, (2018) http://www.jshnc.umin.ne.jp/pdf/HNCreport_2018.pdf . Accessed October 2022
Lim SC, Zhang S, Ishii G et al (2004) Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. Clin Cancer Res 10:166–172
pubmed: 14734465
doi: 10.1158/1078-0432.CCR-0533-3
Goto M, Hasegawa Y, Terada A et al (2005) Prognostic significance of late cervical metastasis and distant failure in patients with stage I and II oral tongue cancers. Oral Oncol 41:62–69
pubmed: 15598587
doi: 10.1016/j.oraloncology.2004.06.007
D’Cruz AK, Vaish R, Kapre N et al (2015) Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med 373:521–529
pubmed: 26027881
doi: 10.1056/NEJMoa1506007
Wushou A, Yibulayin F, Sheng L et al (2021) Elective neck dissection improves the survival of patients with T2N0M0 oral squamous cell carcinoma: a study of the SEER database. B.M.C. Cancer 21:1309
doi: 10.1186/s12885-021-09053-3
Kurokawa H, Yamashita Y, Takeda S et al (2002) Risk factors for late cervical lymph node metastases in patients with stage I or II. Head Neck 24:731–736
pubmed: 12203797
doi: 10.1002/hed.10130
Hori Y, Kubota A, Yokose T (2017) Predictive significance of tumor depth and budding for late Lymoh node metastases in patients with clinical N0 early oral tongue carcinoma. Head Neck 11:477–486
Nguyen KA, Le KQ (2022) Predictive factors of occult cervical lymph node metastasis in tongue cancer. Oral Sci Int, 1–7
Liu S, Liu L, Ye W et al (2016) High vimentin expression associated with lymph node metastasis and predicated a poor prognosis in oral squamous cell carcinoma. Sci Rep 6:38834
pubmed: 27966589
pmcid: 5155220
doi: 10.1038/srep38834
Aiello NM, Kang Y (2019) Context-dependent EMT programs in cancer metastasis. J Exp Med 216:1016–1026
pubmed: 30975895
pmcid: 6504222
doi: 10.1084/jem.20181827
Zhou Y, Liao Q, Han Y et al (2016) Rac1 overexpression is correlated with epithelial mesenchymal transition and predicts poor prognosis in non-small cell lung cancer. J Cancer 7:2100–2109
pubmed: 27877226
pmcid: 5118674
doi: 10.7150/jca.16198
Leng R, Liao G, Wang H et al (2015) Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome. Med Oncol 32:329
pubmed: 25585684
doi: 10.1007/s12032-014-0329-5
Rajamani R, Berrier A, Alahari SK (2011) Role of Rho GTPase and their regulators in cancer progression. Front Biosci 16:2561–2571
doi: 10.2741/3872
Bustelo XR, Sauzeau V, Berenjeno IM (2007) GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. BioEssays 29:356–370
pubmed: 17373658
pmcid: 1971132
doi: 10.1002/bies.20558
Ehrlich JS, Hansen MD, Nelson WJ (2002) Spation-temporal regulation of Rac1 localization and lamellipodia dynamics during Epithlial cell-cell adhesion. Dev Cell 3:259–270
pubmed: 12194856
pmcid: 3369831
doi: 10.1016/S1534-5807(02)00216-2
Bid HK, Roberts RD, Manchanda PK et al (2013) Rac1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis. Mol Cancer Ther 12:1925–1934
pubmed: 24072884
doi: 10.1158/1535-7163.MCT-13-0164
Ridley AJ (2001) Rho GTPases and cell migration. J Cell Sci 114:2713–2722
pubmed: 11683406
doi: 10.1242/jcs.114.15.2713
Yang WH, Lan HY, Huang CH et al (2012) RAC1 activation mediates Twist1-induced cancer cell migration. Nat Cell Biol 14:366–374
pubmed: 22407364
doi: 10.1038/ncb2455
Yang Q, Luo GY, Li Y et al (2013) Expression of Rac-1 related to tumor depth, lymph node metastasis and patient prognosis in esophageal squamous cell carcinoma. Med Oncol 30:689
pubmed: 24026656
doi: 10.1007/s12032-013-0689-2
Schnelzer A, Prechtel D, Knaus U et al (2000) Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 19:3013–3020
pubmed: 10871853
doi: 10.1038/sj.onc.1203621
Crnogorac-Jurcevic T, Efthimiou E, Capelli P et al (2001) Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 20:7437–7446
pubmed: 11704875
doi: 10.1038/sj.onc.1204935
Zhou K, Rao J, Zhou ZH et al (2018) Rac1-GTP promotes epithelial-mesenchymal transition and invasion of colorectal cancer by activation of STAT3. Lab Invest 98:989–998
pubmed: 29884911
doi: 10.1038/s41374-018-0071-2
Ji J, Feng X, Shi M et al (2015) Rac1 is correlated with aggressiveness and a potential therapeutic target for gastric cancer. Int J Oncol 46:1343–1353
pubmed: 25585795
doi: 10.3892/ijo.2015.2836
Toyama Y, Kontani K, Katada T et al (2019) Conformational landscape alternations promote oncogenic activities of Ras-related C3 botulinum toxin substrate 1 as revealed by NMR. Sci Adv 5:eaav8945
pubmed: 30891502
pmcid: 6415961
doi: 10.1126/sciadv.aav8945
Matsuoka Y, Al-Shareef H, Kogo M et al (2021) Effects of decreased Rac activity and malignant state on oral squamous cell carcinoma in vitro. PLoS ONE 16:e0212323
pubmed: 33444335
pmcid: 7808617
doi: 10.1371/journal.pone.0212323
Liu SY, Yen CY, Yang SC et al (2004) Overexpression of Rac-1 small GTPase binding protein in oral squamous cell carcinoma. J Oral Maxillofac Surg 62:702–707
pubmed: 15170282
doi: 10.1016/j.joms.2004.02.002
Lydiatt WM, Patel SG, O’Sullivan B, et al (2017) Head and neck cancers-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. C.A. Cancer J Clin, 67: 122–37
Yoon C, Cho SJ, Chang KK et al (2017) Role of Rac1 pathway in epithelial-to-mesenchymal transition and cancer stem-like cell phenotypes in gastric adenocarcinoma. Mol Cancer Res 15:1106–1116
pubmed: 28461325
pmcid: 5540756
doi: 10.1158/1541-7786.MCR-17-0053
Tobar N, Villar V, Santibanez JF (2010) ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol Cell Biochem 340:195–202
pubmed: 20204677
doi: 10.1007/s11010-010-0418-5
Zhu G, Wang Y, Huang B et al (2012) A Rac1/PAK1 cascade controls β-catenin activation in colon cancer cells. Oncogene 31:1001–1012
pubmed: 21822311
doi: 10.1038/onc.2011.294
Jaffe AB, Hall A (2005) Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 21:247–269
pubmed: 16212495
doi: 10.1146/annurev.cellbio.21.020604.150721
Gastonguay A, Berg T, Hauser AD et al (2012) The role of Rac1 in the regulation of NF-κB activity, cell proliferation, and cell migration in non-small cell lung carcinoma. Cancer Biol Ther 13:647–656
pubmed: 22549160
pmcid: 3408971
doi: 10.4161/cbt.20082
Kaneto N, Yokoyama S, Hayakawa Y et al (2014) Rac1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer. Cancer Sci 105:788–794
pubmed: 24750242
pmcid: 4317907
doi: 10.1111/cas.12425
Kogai T, Liu YY, Mody K et al (2012) Regulation of sodium iodide symporter gene expression by Rac1/p38β mitogen-activated protein kinase signaling pathway in MCF-7 breast cancer cells. J Biol Chem 287:3292–3300
pubmed: 22157753
doi: 10.1074/jbc.M111.315523
Bauer NN, Chen YW, Samant RS et al (2007) Rac1 activity regulates proliferation of aggressive metastatic melanoma. Exp Cell Res 313:3832–3839
pubmed: 17904119
doi: 10.1016/j.yexcr.2007.08.017
LoPiccolo J, Blumenthal GM, Bernstein WB et al (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Upda 11:32–50
doi: 10.1016/j.drup.2007.11.003
Serafino A (2012) New molecular biomarkers candidates for the development of multiparametric platforms for hepatocellular carcinoma diagnosis, prognosis and personalised therapy. http://cancerlink.ru/ennew-molecular-biomarkers-for-hepatocellular-carcinoma-diagnosis.html . Accessed October 2022
Le PN, McDermott JD, Jimeno A (2015) Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther 146:1–11
pubmed: 25172549
doi: 10.1016/j.pharmthera.2014.08.005
Kamai T, Shirataki H, Nakanishi K et al (2010) Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer. B.M.C. Cancer 10:164
doi: 10.1186/1471-2407-10-164
Du X, Wang S, Lu J et al (2012) Clinical value of Tiam1-Rac1 signaling in primary gallbladder carcinoma. Med Oncol 29:1873–1878
pubmed: 21853342
doi: 10.1007/s12032-011-0046-2
Ueno H, Murphy J, Jass JR et al (2002) Tumor ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40:127–132
pubmed: 11952856
doi: 10.1046/j.1365-2559.2002.01324.x
Grigore AD, Jolly MK, Jia D et al (2016) Tumor budding: the name is EMT. Partial EMT J Clin Med 5:51
pubmed: 27136592
doi: 10.3390/jcm5050051
Head and Neck Cancers Version 1, (2022) National Comprehensive Cancer Network (NCCN)
Zenga J, Divi V, Stadler M et al (2019) Lymph node yield, depth of invasion, and survival in node-negative oral cavity cancer. Oral Oncol 98:125–131
pubmed: 31586894
doi: 10.1016/j.oraloncology.2019.09.028